+A -A

Tabela:
Comparative View:

3Q20 Create chart
Net sales revenues 1,778,026
Change in Fair Value of Biological Assets 15,751
Cost of Goods Sold -1,069,059
Depreciation / Amortization / exhaustion -121,936
Exhaustion of biological assets -25,486
Gross Profit 577,296
Selling Expenses -212,051
General and Administrative Expenses -56,394
Management Compensation -4,327
Other Operating Compensation -33,940
Equity income from subsidiaries -43,339
Operating Profit before Financial Income and Equity 227,245
Financial Income 26,474
Financial Expenses -59,415
Income Before Income Tax and Social Contribution 194,304
Income and social contribution taxes - current -69,090
Income Tax and Social Contribution - Deferred -1,275
Effect profit from discontinued operation 0
Net Income 123,939
Recurring Net Income 175,719
Recurring EBITDA 433,787
EBITDA Margin 24.4 %

* Because of the date of the merger between Duratex and Satipel, 31.08.09, include data only from the "old" Duratex

**from 1Q 12 the data does not include discontinued operation, Deca Piazza